Melanotan II vs PT-141: Melanocortin Research Compared

Both compounds act on the melanocortin receptor family, which comprises five subtypes with different tissue distributions and functions:

Neither MT-II nor PT-141 activates MC2R (that receptor is exclusive to ACTH). Both activate MC3R and MC4R. The key difference is at MC1R.

Melanotan II (MT-II) is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona beginning in the 1980s. Its structure is a cyclic heptapeptide — the cyclisation confers resistance to exopeptidase degradation and contributes to a longer biological half-life than linear melanocortin peptides.

MT-II activates MC1R, MC3R, MC4R, and MC5R. The MC1R activation drives eumelanin synthesis in melanocytes — the tanning/pigmentation effect that MT-II was originally developed to study, as part of research into photoprotection and melanoma prevention. The MC3R and MC4R activation produces the central nervous system effects that characterise MT-II in research contexts: behavioural arousal, appetite suppression, and autonomic effects in animal models.

The observation that MT-II acted through central melanocortin receptors rather than through vascular mechanisms was documented in early human studies (Wessells et al., 1998), and prompted the development of more receptor-selective derivatives — of which PT-141 is the most studied.

PT-141 is a cyclic lactam derivative of MT-II, developed to increase selectivity for the central MC3R/MC4R pathways while reducing the MC1R-mediated pigmentation effects that complicate research into the CNS-active properties of melanocortin peptides.

The structural change — introduction of a lactam bridge — reduces MC1R engagement relative to MT-II while preserving the MC3R and MC4R activity. The result is a compound that produces the central melanocortin receptor effects of MT-II with substantially less pigmentation activity.

PT-141 is the only compound in this compound class to have progressed through full human clinical development. It received FDA approval in 2019 as bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women. This approval generated an extensive published pharmacokinetic and pharmacodynamic dataset from Phase 2 and Phase 3 trials — a level of human clinical data that MT-II does not have.

Published PK data from the FDA approval programme: biological t½ approximately 2.7 hours following subcutaneous administration, peak plasma concentration at approximately 1 hour, dose-dependent central melanocortin receptor engagement confirmed.

Melanotan II is the appropriate compound when research requires engagement across the full melanocortin receptor profile — including MC1R-mediated pigmentation pathways. It remains relevant for research examining melanocyte biology, eumelanin synthesis, the relationship between photoprotection and melanocortin receptor activation, and broad-spectrum melanocortin pharmacology. The MC5R engagement also makes it relevant for exocrine gland research where PT-141 is less well-characterised.

PT-141 is the appropriate compound when research focuses specifically on the MC3R/MC4R-mediated central melanocortin pathways — particularly sexual arousal neuroscience, energy homeostasis, and related behavioural or endocrine models — where MC1R activation and pigmentation confounders are not desired. The extensive published human clinical data from the Vyleesi approval programme provides a pharmacokinetic and safety baseline unavailable for MT-II.

Both compounds are cyclic, which confers structural resistance to exopeptidase degradation. Both require reconstitution and cold-chain storage. See How to Reconstitute a Research Peptide → and the Peptide Storage Guide →.